FLT3-ITD阳性儿童急性髓系白血病中共存突变的预后影响
研究在儿童肿瘤协作组试验中纳入464例FLT3-ITD阳性急性髓系白血病儿童及年轻患者,分析共存突变谱与预后。79%患者存在239个不同基因的共存突变。携带NPM1、CEBPA、t(8;21)或inv(16)有利风险突变者5年无事件生存率为64%,显著优于WT1、UBTF或NUP98::NSD1不良风险突变者的22.2%及中间组40.9%(P均<.001)。多变量分析显示共存突变有显著预后影响而等位基因比率无影响。
要点
- FLT3-ITD阳性AML中79%患者存在共存突变,共存突变谱显著影响预后。
- 有利风险共存突变者5年EFS 64%,不良风险突变者22.2%,中间组40.9%(P均<.001)。
- 缓解期巩固移植可显著改善生存,但NUP98::NSD1共存者强化治疗(含索拉非尼)仍预后差。
核心结论
- FLT3-ITD阳性AML的共存突变谱具有显著预后影响,对风险分层和治疗分配至关重要。
- 多变量分析显示共存突变有显著预后影响,而等位基因比率无影响。
研究设计与样本
- 研究纳入464例在儿童肿瘤协作组试验中治疗、具有测序和结局数据的FLT3-ITD突变患者。
- 根据共存风险分层突变的存在情况确定总生存、无事件生存和复发风险。
- 试验注册号:NCT00002798、NCT00070174、NCT00372593、NCT01371981。
主要发现
- 79%的患者在239个不同基因中存在通过突变或融合导致的共存改变。
- 携带NPM1、CEBPA、t(8;21)或inv(16)有利风险共存突变的FLT3-ITD阳性AML患者5年EFS为64%。
- 携带WT1、UBTF或NUP98::NSD1不良风险突变的FLT3-ITD阳性AML患者5年EFS为22.2%。
- 缺乏有利或不良风险突变的FLT3-ITD阳性中间组患者5年EFS为40.9%。
- 有利风险组5年EFS 64%显著优于不良风险组22.2%和中间组40.9%(P均<.001)。
关键数值与推荐
- 有利风险共存突变:NPM1、CEBPA、t(8;21)或inv(16)。
- 不良风险共存突变:WT1、UBTF或NUP98::NSD1。
- 中间组:缺乏有利风险或不良风险突变(ITDpos中间)。
临床怎么用
- 原文结论指出共存突变谱对FLT3-ITD阳性AML的风险分层和治疗分配至关重要。
- 原文报告缓解期巩固移植的强化治疗显著改善FLT3-ITD阳性AML生存。
- 原文报告ITDpos/NUP98::NSD1患者接受包括索拉非尼在内的强化治疗仍预后差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We sought to define the cooccurring mutational profile of FLT3-ITD-positive (ITDpos) acute myeloid leukemia (AML) in pediatric and young adult patients and to define the prognostic impact of cooperating mutations. We identified 464 patients with FLT3-ITD mutations treated on Children's Oncology Group trials with available sequencing and outcome data. Overall survival, event-free survival (EFS), and relapse risk were determined according to the presence of cooccurring risk stratifying mutations. Among the cohort, 79% of patients had cooccurring alterations across 239 different genes that were altered through mutations or fusions. Evaluation of the prognostic impact of the cooccurring mutations demonstrated that patients with ITDpos AML experienced significantly different outcomes according to the cooccurring mutational profile. Patients with ITDpos AML harboring a cooccurring favorable-risk mutation of NPM1, CEBPA, t(8;21), or inv(16) experienced a 5-year EFS of 64%, which was significantly superior to of 22.2% for patients with ITDpos AML and poor-risk mutations of WT1, UBTF, or NUP98::NSD1 as well to 40.9% for those who lacked either favorable-risk or poor-risk mutation (ITDpos intermediate; P < .001 for both). Multivariable analysis demonstrated that cooccurring mutations had significant prognostic impact, whereas allelic ratio had no impact. Therapy intensification, specifically consolidation transplant in remission, resulted in significant improvements in survival for ITDpos AML. However, patients with ITDpos/NUP98::NSD1 continued to have poor outcomes with intensified therapy, including sorafenib. Cooccurring mutational profile in ITDpos AML has significant prognostic impacts and is critical to determining risk stratification and therapeutic allocation. These clinical trials were registered at www.clinicaltrials.gov as NCT00002798, NCT00070174, NCT00372593, and NCT01371981.
引用
- Tarlock K, Gerbing RB, Ries RE, et al. Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia. Blood Adv. 2024. PMID: 38295280. doi:10.1182/bloodadvances.2023011980
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。